MedPath

Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Registration Number
NCT00757341
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SKI-606SKI-606-
Primary Outcome Measures
NameTimeMethod
Mass Balance and Metabolic Disposition10 days
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath